Cashing in on your genes
By Mark Henderson,
The Times
| 01. 07. 2010
Spitting is not an activity that has traditionally carried much social cachet. Yet at New York Fashion Week and the Davos World Economic Forum two years ago, an invitation to drool into a tube became one of the hottest tickets around. For Hollywood celebrities and business executives alike, the new place to see and be seen was at a "spit party".
At this 21st-century take on the Tupperware party guests would hand over a little saliva (and a few hundred dollars) to a Silicon Valley start-up called 23andMe. After the cocktails had slipped down the company would extract DNA from the VIP spittle to assess its new customers' chances of developing a hundred or so medical conditions and physical traits, from breast cancer to baldness.
The idea was one whose time seemed to have come. As science started to reveal how genetic influences shape our health, so a new breed of business was taking DNA out of the laboratory and turning it into a glamorous consumer product. Anne Wojcicki and Linda Avey, the telegenic founders of 23andMe, were soon extolling...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
